This activity is for healthcare professionals outside of the UK only.

This activity is funded by an independent medical education grant from Abbott Diabetes Care Inc.
The activity is jointly provided by USF Health and touchIME.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues. Select a language to continue.

    Downloads
    Download Slides
    Download Practice Aid
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Stewart Harris

    Western University, London, Canada

    Stewart Harris is a professor in the Department of Family Medicine, with cross appointments in the Departments of Epidemiology and Biostatistics and the Division of Endocrinology and Metabolism/Medicine, at the Schulich School of Medicine and Dentistry, Western University in London, Ontario, Canada. He is a fellow of the Canadian Academy of Health Sciences. read more

    Prof. Harris is also a research scientist at the Lawson Health Research Institute and lead physician and medical director of the Primary Care Diabetes Support Program at St. Joseph’s Health Care, London, Ontario – an integrated team-based diabetes clinic for disenfranchised and marginalized populations, which he founded in 2007. His research programme focuses on three priority areas: diabetes research with indigenous peoples, hypoglycaemia research and clinical trials.

    Prof. Harris has published over 315 articles in peer-reviewed journals and participated extensively in clinical practice guideline development, including serving as chair and executive of the Canadian Diabetes Association clinical practice guidelines committee for 15 years. He is the recipient of the Ontario Ministry of Health Career Scientist award, the Dr Gerald S. Wong Service Award of the Canadian Diabetes Association and the Hellmuth Prize for Achievement in Research at Western University. In July 2015, Prof. Harris was appointed to the Order of Canada for his contributions to the development of strategies to manage and reduce diabetes in Aboriginal communities and other vulnerable populations.

    Prof. Stewart Harris discloses: Advisory board or Panel fees from Abbott, AstraZeneca, Bayer Inc., Dexcom, Eli Lilly and Company, HLS Therapeutics, Janssen, Novo Nordisk, Sanofi and Applied Therapeutics (relationship terminated). Consultancy fees from Abbott, AstraZeneca, Bayer Inc., Dexcom, Eli Lilly and Company, HLS Therapeutics, Janssen, Novo Nordisk and Sanofi. Grants/Research Support from Abbott, Applied Therapeutics Inc., AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novartis, Novo Nordisk and Sanofi.
    Dr Anders Carlson

    International Diabetes Center, Minneapolis, MN, USA

    Anders Carlson is an adult endocrinologist, an associate executive director at the International Diabetes Center (IDC) at HealthPartners and an associate professor at the University of Minnesota Medical School, Minneapolis, MN, USA. read more

    Dr Carlson is a member of the American Diabetes Association, Endocrine Society and American Association of Clinical Endocrinologists. His current research efforts are centred on diabetes technology, prevention and education. He is a principal investigator on several clinical trials exploring new diabetes therapeutics, as well as devices such as automated insulin delivery systems and continuous glucose monitoring in special populations. In conjunction with the IDC team, he has published several articles about glucose data interpretation and use of the Ambulatory Glucose Profile.

    Dr Anders Carlson discloses: Advisory board or Panel fees from MannKind and Novo Nordisk. Grants/research support fees from Abbott, Dexcom, Eli Lilly, Insulet, Medtronic, Novo Nordisk, Sanofi and Tandem Diabetes Care.
    Prof. Shannon Izdik

    University of Maryland School of Nursing, Baltimore, MD, USA

    Shannon Idzik is a nurse practitioner and Professor of Organizational Systems and Adult Health at the University of Maryland, Baltimore, MD, USA. She is also the Associate Dean of the Doctorate in Nursing Practice (DNP) Program at the University of Maryland and current president of the National Organization of Nurse Practitioner Faculties. read more

    She received her degree in nursing from York College of Pennsylvania, and her master’s degree as an adult primary care nurse practitioner and DNP from the University of Maryland.

    Prof. Idzik has worked clinically as a nurse practitioner in bariatric surgery, endocrinology, primary care, aesthetics, pre-operative health and emergency medicine.

    She has presented and authored numerous publications and currently serves as the managing editor of the Journal of Doctoral Nursing Practice. She is a reviewer for the Journal of Advanced Nursing, the Journal of Professional Nursing and the Journal for Nurse Practitioners. Prof. Idzik has also served as the secretary and president of the Nurse Practitioner Association of Maryland.

    Prof. Shannon Izdik has no financial interests/relationships or affiliations to disclose in relation to this activity.
    Back to Faculty
    touchENDOCRINOLOGY touchENDOCRINOLOGY
    Start activity

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    What beneficial changes do you see in your T2D patients after initiating CGM?

    Submit your answer to see the results

    Dietary changes and/or weight loss
       
    Improvement in A1c and increased patient control over their A1c management
       
    Improved cardiovascular and/or renal outcomes
       
    All/more than one of the above options
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    What is the most common reason for you not initiating CGM in your T2D patients?

    Submit your answer to see the results

    Limited time for patient consultations
       
    Challenging for me to interpret the data
       
    Cost of CGM is prohibitive to the patient
       
    No implementation protocol in my clinical practice/Other reason
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    What % of your T2D patients taking insulin also use continuous glucose monitoring?

    Submit your answer to see the results

    None
       
    <25%
       
    25–50%
       
    >50%
       
     
    Video Take ACPE Test
    Diabetes CE/CME accredited

    touchPANEL DISCUSSION
    A visually engaging discussion designed to emulate a ‘live’ panel experience and provide clinicians with practical expert insights to address their clinical challenges. Useful tips below will show how to navigate the activity. Close

    Continuous glucose monitoring in type 2 diabetes: Overcoming barriers to optimize outcomes

    Faculty Podcast Featured
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Describe the benefits of CGM in patients with type 2 diabetes
    • Apply strategies to overcome barriers to CGM to help increase uptake in patients with type 2 diabetes, including timely referral of eligible patients
    • Support patients with type 2 diabetes who are undertaking CGM through effective communication and collaboration with the primary and secondary care teams
    Overview

    In this activity, three experts provide their perspectives on the benefits of CGM in patients with T2D, strategies to overcome the barriers to its uptake and how to best support patients in implementing CGM. The discussion is guided by questions from HCPs involved in the management of patients with T2D.

    This activity is jointly provided by USF Health and touchIME. read more

    Target Audience

    This activity has been designed to meet the educational needs of endocrinologists, diabetologists, primary care physicians, pharmacists and diabetes nurse specialists involved in the management of type 2 diabetes.

    Disclosures

    USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

    Faculty

    Prof. Stewart Harris discloses: Advisory board or Panel fees from Abbott, AstraZeneca, Bayer Inc., Dexcom, Eli Lilly and Company, HLS Therapeutics, Janssen, Novo Nordisk, Sanofi and Applied Therapeutics (relationship terminated).Consultancy fees from Abbott, AstraZeneca, Bayer Inc., Dexcom, Eli Lilly and Company, HLS Therapeutics, Janssen, Novo Nordisk and Sanofi.Grants/Research Support from Abbott, Applied Therapeutics Inc., AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novartis, Novo Nordisk and Sanofi.

    Dr Anders Carlson discloses: Advisory board or Panel fees from MannKind and Novo Nordisk. Grants/research support fees from Abbott, Dexcom, Eli Lilly, Insulet, Medtronic, Novo Nordisk, Sanofi and Tandem Diabetes Care.

    Prof. Shannon Izdik has no financial interests/relationships or affiliations to disclose in relation to this activity.

    Content reviewer

    Kaitlyn E Rechenberg, PhD, MPH, APRN has no financial interests/relationships or affiliations in relation to this activity.

    Touch Medical Contributors

    Sola Neunie has no financial interests/relationships or affiliations in relation to this activity.

    USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

    Requirements for Successful Completion

    In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

    If you have questions regarding credit please contact cpdsupport@usf.edu. 

    Accreditations

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

    USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Advanced Practice Providers

    Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

    The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

    Pharmacists

    USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 0.75 contact hours (0.75 CEUs). Universal program number is as follows: 0230-0000-24-006-H01-P.

    Nurses

    USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    A maximum of 0.75 contact hour(s) may be earned by learners who successfully complete this  continuing professional development activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.

    This activity is awarded 0.75 ANCC pharmacotherapeutic contact hour.

    EBAC® Accreditation

    touchIME is an EBAC® accredited provider since 2023.

    This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 0.75 hours of effective education time.
    The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.

    Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.

    Faculty Disclosure Statement / Conflict of Interest Policy

    In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.

    Requirements for Successful Completion

    Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.

    Date of original release: 29 August 2024. Date credits expire: 29 August 2025.

    Time to complete: 39 minutes

    If you have any questions regarding credit please contact cpdsupport@usf.edu.

    If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org.

     

    This activity is CE/CME accredited

    To obtain contact hours from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    CONFERENCE HUB

    Benefits of finerenone for patients with type 2 diabetes, cardiovascular, kidney and metabolic complications

    GO TO HUB

    touchIN CONVERSATION

    Elevating the role of basal insulin therapy in T2D management: From CGM use to fixed-ratio combinations and once-weekly regimens

    This activity is CE/CME accredited
    LAUNCH ACTIVITY
    Dr Hamdy ADA thumbnail

    CONFERENCE HUB

    Osama Hamdy, ADA 2022: Tirzepatide for obesity in the SURMOUNT-1 study and remission in type 2 diabetes

    GO TO HUB

    touchMDT

    Integrating GLP-1 RAs into T2D management: A unified approach, from PCP to patient

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    JOURNALS

    The Challenge of Lipid Management in Patients with Diabetes or Other Endocrine Disorders

    GO TO ARTICLE

    JOURNALS

    The Diabetic Foot—Imaging Options and Considerations

    GO TO ARTICLE

    Topics covered in this activity

    Diabetes
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 10 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This Activity Is Funded By:

    An independent medical education grant from Abbott Diabetes Care Inc.
    This activity is jointly provided by USF Health and touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    EBAC® 

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    touchIME is an EBAC® accredited provider since 2023.

    This content is intended for healthcare professionals.

    Date of original release: 29 August 2024. Date credits expire: 29 August 2025.

    Claim Credit
    touchPANEL DISCUSSION
    Continuous glucose monitoring in type 2 diabetes: Overcoming barriers to optimize outcomes
    0.75 CE/CME credit
    Question 1/4
    You are discussing the potential use of CGM with your patient with type 2 diabetes. They ask you why their HbA1c reading is no longer enough to determine their blood sugar level. What would you tell them?

    CGM, continuous glucose monitoring; HbA1c, glycated haemoglobin.

    CGM provides information on daily glucose fluctuations and can show how glucose concentrations are affected by everyday activities and stress levels.1 HbA1c readings reflect the average blood glucose concentration over 2–3 months and do not address glycaemic variability.2 In addition, HbA1c is not a significant predictor of hypoglycaemia.3 Differences between individuals in the binding of glucose to RBCs and RBC turnover can lead to variation in HbA1c, meaning it is difficult for clinicians to treat type 2 diabetes based on the HbA1c score alone.2,4

    Abbreviations

    CGM, continuous glucose monitoring; HbA1c, glycated haemoglobin; RBC, red blood cell.

    References

    1. Suh S, Kim JH. Diabetes Metab J. 2015;39:273–82. 
    2. Kushner PR, Kruger DF. Clin Diabetes. 2020;38:348–56. 
    3. Khunti K, et al. Diabetes Obes Metab. 2016;18:907–15. 
    4. Bergenstal RM, et al. Diabetes Care. 2018;41:2275–80.
    Question 2/4
    You have a patient with type 2 diabetes who is being managed with canagliflozin monotherapy, but is struggling to achieve their glycaemic targets. They mention that someone in their diabetes patient support group on basal insulin has recently started using CGM and it has already improved their HbA1c levels. They ask you if CGM could help them. What would you tell them?

    CGM, continuous glucose monitoring; HbA1c, glycated haemoglobin.

    Data from the 2024 American Diabetes Association Scientific Session demonstrate that the use of CGM in patients with type 2 diabetes who are not receiving insulin can reduce HbA1c and time-above range (>180 mg/dL), as well as improve time-in-range (70–180 mg/dL).1,2 In addition to glycaemic benefits, other studies have demonstrated that intermittent use of CGM in nonintensively treated type 2 diabetes results in modification of user behaviour in relation to lifestyle and food choices, as well as improved understanding of their diabetes.3

    Abbreviations

    CGM, continuous glucose monitoring; HbA1c, glycated haemoglobin. 

    References

    1. Norman GJ, et al. Diabetes. 2024;73(Suppl.1):143-OR. 
    2. Martens TW, et al. Diabetes. 2024;73(Suppl.1):356-OR.
    3. Aleppo G, et al. Diabetes Technol Ther. 2023;25:741–51.
    Question 3/4
    You are discussing CGM with a fellow HCP. They tell you that they are reluctant to recommend CGM to their patients with type 2 diabetes as they find AGP reports challenging to interpret. You decide to show them an example AGP report from an HCP education website. How would you explain it to them? “The AGP report provides…”

    AGP, ambulatory glucose profile; CGM, continuous glucose monitoring; HbA1c, glycated haemoglobin; HCP, healthcare professional.

    AGP reports provide a range of data for interpretation. The standardized AGP report incorporates all core CGM metrics (i.e. average glucose, glucose management indicator, glucose variability and time-in-ranges) and targets, along with a 14-day composite glucose profile to support clinical decision-making. 

    Abbreviations

    AGP, ambulatory glucose profile; CGM, continuous glucose monitoring.

    Reference

    Battelino T, et al. Diabetes Care. 2019;42:1593–603.

    Question 4/4
    You have a 62-year old patient who is currently managing his type 2 diabetes with oral antidiabetes agents and basal insulin. He has a manual job, so regular fingerstick testing is inconvenient. He was fitted with a CGM sensor at his previous visit 2 weeks ago. On his first follow-up visit, he asks for help interpreting the data. How would you best support this patient?

    CGM, continuous glucose monitoring; HbA1c, glycated haemoglobin.

    The American Diabetes Association 2024 guidelines state that patients with more education regarding device use have better outcomes and therefore, the need for additional education should be periodically assessed, particularly if outcomes are not being met.1 Diabetes care and education specialists and/or pharmacists who are well-versed in CGM may assist in interpretation of the results, for example preventing overcorrection of high glucose, how and when to share the data and understanding CGM reports.2,3

    Abbreviation

    CGM, continuous glucose monitoring.

    References

    1. American Diabetes Association Professional Practice Committee. Diabetes Care. 2024;47(Suppl.1):S126–44.
    2. Cox C, et al. Association of Diabetes Care & Education Specialists. November 2023. Available at: www.adces.org/danatech/glucose-monitoring/continuous-glucose-monitors-(cgm)/cgms-in-professional-practice/cgm-the-dces-role (accessed 22 July 2024).
    3. Cook K, Ogurchak J. Pharmacy Times. November 2021. Available at: www.pharmacytimes.com/view/continuous-glucose-monitoring-an-opportunity-to-understand-and-individualize-diabetes-management (accessed 22 July 2024).
    Back to Activity

    You may also be interested in...

    CONFERENCE HUB

    Diana Isaacs, ADCES 2022: Clinical strategies on optimal treatment and prevention of hypoglycemia

    GO TO HUB

    CONFERENCE HUB

    Silva Arslanian, ADA 2022: Lifestyle-focused interventions in young patients with type 2 diabetes and the challenges for treatment

    GO TO HUB

    touchMDT

    Integrating GLP-1 RAs into T2D management: A unified approach, from PCP to patient

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchMDT

    Antihyperglycemic therapy in the patient with T2D and obesity: A multidisciplinary outlook

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    JOURNALS

    The Role of Individualized Exercise Prescription in Type 2 Diabetes Mellitus Management

    GO TO ARTICLE

    JOURNALS

    Pharmacologic Treatment of Diabetic Nephropathy

    GO TO ARTICLE
    This Activity Is Funded By:

    An independent medical education grant from Abbott Diabetes Care Inc.
    This activity is jointly provided by USF Health and touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    EBAC® 

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    touchIME is an EBAC® accredited provider since 2023.

    This content is intended for healthcare professionals.

    Date of original release: 29 August 2024. Date credits expire: 29 August 2025.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup